$53.27
0.50% today
Nasdaq, Feb 28, 07:47 pm CET
ISIN
US76243J1051
Symbol
RYTM
Sector
Industry

Rhythm Pharmaceuticals, Inc. Target price 2025 - Analyst rating & recommendation

Rhythm Pharmaceuticals, Inc. Classifications & Recommendation:

Buy
91%
Hold
9%

Rhythm Pharmaceuticals, Inc. Price Target

Target Price $74.73
Price $53.00
Potential
Number of Estimates 11
11 Analysts have issued a price target Rhythm Pharmaceuticals, Inc. 2026 . The average Rhythm Pharmaceuticals, Inc. target price is $74.73. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 11 analysts: 10 Analysts recommend Rhythm Pharmaceuticals, Inc. to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Rhythm Pharmaceuticals, Inc. stock has an average upside potential 2026 of . Most analysts recommend the Rhythm Pharmaceuticals, Inc. stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Revenue Million $ 130.13 186.47
68.06% 43.29%
Net Margin -208.08% -86.16%
19.30% 58.59%

11 Analysts have issued a sales forecast Rhythm Pharmaceuticals, Inc. 2025 . The average Rhythm Pharmaceuticals, Inc. sales estimate is

$186m
Unlock
. This is
43.29% higher
Unlock
than the revenue of the last 12 months(TTM). The highest sales forecast is
$207m 59.38%
Unlock
, the lowest is
$178m 36.79%
Unlock
.

This results in the following potential growth metrics:

Revenue Estimates

2024 $130m 68.06%
2025
$186m 43.29%
Unlock
2026
$314m 68.40%
Unlock
2027
$594m 89.10%
Unlock
2028
$991m 66.84%
Unlock
2029
$1.4b 41.63%
Unlock

4 Rhythm Pharmaceuticals, Inc. Analysts have issued a net profit forecast 2025. The average Rhythm Pharmaceuticals, Inc. net profit estimate is

$-161m
Unlock
. This is
40.94% higher
Unlock
than the net profit for the last 12 months(TTM). The highest net profit forecast is
$-129m 52.52%
Unlock
, the lowest is
$-197m 27.75%
Unlock
.

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-271m 35.63%
2025
$-161m 40.67%
Unlock
2026
$-71.3m 55.63%
Unlock
2027
$132m 285.84%
Unlock
2028
$412m 211.00%
Unlock
2029
$596m 44.78%
Unlock

Net Margin

2024 -208.08% 19.30%
2025
-86.16% 58.59%
Unlock
2026
-22.70% 73.65%
Unlock
2027
22.31% 198.28%
Unlock
2028
41.58% 86.37%
Unlock
2029
42.51% 2.24%
Unlock

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually
Dec '24 2025
Estimates
Earnings Per Share $ -4.34 -2.58
35.63% 40.55%
P/E negative
EV/Sales 16.54

4 Analysts have issued a Rhythm Pharmaceuticals, Inc. forecast for earnings per share. The average Rhythm Pharmaceuticals, Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is

$-2.58
Unlock
. This is
40.83% higher
Unlock
than earnings per share in the financial year 2024. The highest <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS forecast is
$-2.07 52.52%
Unlock
, the lowest is
$-3.15 27.75%
Unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-4.34 35.63%
2025
$-2.58 40.55%
Unlock
2026
$-1.14 55.81%
Unlock
2027
$2.12 285.96%
Unlock
2028
$6.60 211.32%
Unlock
2029
$9.56 44.85%
Unlock

P/E ratio

Current -12.16 13.64%
2025
-20.58 69.24%
Unlock
2026
-46.39 125.41%
Unlock
2027
24.96 153.80%
Unlock
2028
8.03 67.83%
Unlock
2029
5.54 31.01%
Unlock

Based on analysts' sales estimates for 2025, the Rhythm Pharmaceuticals, Inc. stock is valued at an <a href=https://blog.stocksguide.com/knowledge/enterprise-value-sales-simply-explained>EV/Sales of

16.54
Unlock
and an <a href=https://blog.stocksguide.com/knowledge/price-sales-ratio-simply-explained>P/S ratio of
17.47
Unlock
.

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 23.69 26.63%
2025
16.54 30.20%
Unlock
2026
9.82 40.62%
Unlock
2027
5.19 47.12%
Unlock
2028
3.11 40.06%
Unlock
2029
2.20 29.39%
Unlock

P/S ratio

Current 25.03 27.38%
2025
17.47 30.21%
Unlock
2026
10.37 40.62%
Unlock
2027
5.49 47.12%
Unlock
2028
3.29 40.06%
Unlock
2029
2.32 29.39%
Unlock

Current Rhythm Pharmaceuticals, Inc. Upgrades & Downgrades Beta

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Needham Locked ➜ Locked Locked Feb 27 2025
Canaccord Genuity Locked ➜ Locked Locked Feb 27 2025
Needham Locked ➜ Locked Locked Feb 24 2025
Needham Locked ➜ Locked Locked Feb 19 2025
JMP Securities Locked ➜ Locked Locked Dec 23 2024
HC Wainwright & Co. Locked ➜ Locked Locked Dec 23 2024
Oppenheimer Locked ➜ Locked Locked Dec 20 2024
Analyst Rating Date
Locked
Needham: Locked ➜ Locked
Feb 27 2025
Locked
Canaccord Genuity: Locked ➜ Locked
Feb 27 2025
Locked
Needham: Locked ➜ Locked
Feb 24 2025
Locked
Needham: Locked ➜ Locked
Feb 19 2025
Locked
JMP Securities: Locked ➜ Locked
Dec 23 2024
Locked
HC Wainwright & Co.: Locked ➜ Locked
Dec 23 2024
Locked
Oppenheimer: Locked ➜ Locked
Dec 20 2024

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today